Aquestive Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Warren, NJ USA
Total Funding:$76.6M
Industry:Pharma
Founded:N/A
Lead Investor(s):BMO Capital Markets, RBC Capital Markets
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Aquestive Therapeutics's revenue is currently $6.7M per year.
  • Aquestive Therapeutics received $73.9M in venture funding in August 2018.
  • Aquestive Therapeutics's revenue per employee is $50299
  • Aquestive Therapeutics's total funding is $76.6M.

Employee Data

  • Aquestive Therapeutics has 134 Employees.
  • Aquestive Therapeutics grew their employee count by 31% last year.
  • Aquestive Therapeutics currently has 1 job openings.

What Is Aquestive Therapeutics?

Aquestive Therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people's lives. Our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. Our initial focus, supported by our current approved products and late stage pipeline, is to address immediate CNS challenges.

keywords:N/A

134

Number of Employees

$6.7M

Revenue (est)

1

Current Jobs

31%

Employee Growth %

$76.6M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
TCP Reliable
$7.8M428%
TCP Reliable
$7.8M428%
Shionogi
$87M4698%
Trio, An FCB He...
$7.8M415%
Vertice Pharma
$7M4117%
Ortho Dermatolo...
$43.2M2297%
PRI Healthcare ...
$11.5M594%
TAIHO ONCOLOGY ...
$35.8M1949%
LEO Pharma Inc....
$42.4M2309%
Specialty Rx
$19.9M11213%

Aquestive Therapeutics News

14-Mar-19 - Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2018

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2018 Earnings Conference Call March 14, 2019 8:00 AM ET. Company Participants.

28-Feb-19 - Aquestive Therapeutics: Specialty Pharma Company With Multiple

Shares of Aquestive Therapeutics (AQST) have lost just over 50% of their value since going public on the Nasdaq in July of 2018 (IPO pricing of

14-Mar-19 - Aquestive Therapeutics Inc. (AQST) Misses Q4 EPS by 5c, Revenues

Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q4 EPS of ($0.56), $0.05 worse than the analyst estimate of ($0.51). Revenue for the

Aquestive Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-08-16$73.9MUndisclosedBMO Capital MarketsArticle

Aquestive Therapeutics Executive Hires

DateNameTitleReference
2018-08-14Sandy CostaChairmanArticle
2018-09-12Lori BraenderSVP General CounselArticle
2019-01-04Gary SlatkoSVP, Chief Medical OfficerArticle